

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice

Paula I Gonzalez-Ericsson^{1*}, Elisabeth S Stovgaard², Luz Sua³, Emily Reisenbichler⁴, Zuzana Kos⁵, Jodi M Carter⁶, Stefan Michiels⁷, John Le Quesne^{8,9}, Torsten O Nielsen¹⁰, Anne-Vibeke Lænkholm¹¹, Stephen Fox^{12,13}, Julien Adam¹⁴, John Bartlett^{15,16}, David L Rimm⁴, Cecily Quinn¹⁷, Dieter Peeters^{18,19}, Maria V Dieci^{20,21}, Anne Vincent-Salomon²², Ian Cree²³, Akira I Hida²⁴, Justin Balko^{1,25,26}, Harry R Haynes^{27,28}, Isabel Frahm²⁹, Gabriela Acosta-Haab³⁰, Marcelo Balancin³¹, Enrique Bellolio³², Wentao Yang³³, Pawan Kirtani³⁴, Tomoharu Sugie³⁵, Anna Ehinger³⁶, Carlos Castaneda³⁷, Marleen Kok³⁸, Heather McArthur³⁹, Kalliopi Siziopikou⁴⁰, Sunil Badve⁴¹, Susan Fineberg⁴², Allen Gown⁴³, Giuseppe Viale^{44,45}, Stuart J Schnitt^{46,47}, Giancarlo Pruneri^{45,48}, Frederique Penault-Llorca^{49,50}, Stephen Hewitt⁵¹, E Aubrey Thompson⁵², Kimberly Allison⁵³, William F Symmans⁵⁴, Andrew M Bellizzi⁵⁵, Edie Brogi⁵⁶, David Moore⁵⁷, Denis Larsimont⁵⁸, Deborah A Dillon⁴⁶, Alexander Lazar⁵², Huangchun Lien⁵⁹, Matthew P Goetz⁶⁰, Glenn Broeckx⁶¹, Khalid El Bairi⁶², Nadia Harbeck⁶³, Ashley Cimino-Mathews⁶⁴, Christos Sotiriou⁶⁵, Sylvia Adams⁶⁶, Shi-wei Liu⁶⁷, Sibylle Loibl⁶⁸, I-Chun Chen⁶⁹, Sunil R Lakhani⁷¹, Jonathan W Juco⁷¹, , Carsten Denkert⁷², Elizabeth F Blackley⁷³, Sandra Demaria⁷, Roberto Leon-Ferre^{60,4}, Oleg Gluz⁷⁵, Dimitrios Zardavas⁷⁶, Kenneth Emancipator⁷¹, Scott Ely⁷⁷, Sherene Loi^{73,78}, Roberto Salgado^{78,79}, Melinda Sanders^{1,26*} on behalf of the International Immuno-Oncology Biomarker Working Group.

¹Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA.

²Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark.

³Department of Pathology, Fundación Valle del Lili, Cali, Colombia.

- ⁴Department of Pathology, Yale School of Medicine, New Haven, USA.
- ⁵Department of Pathology, BC Cancer Agency, Vancouver, Canada
- ⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.
- ⁷Biostatistics and Epidemiology Service, Centre de Recherche en Epidémiologie et Santé des Populations, Gustave Roussy, Université Paris-Sud, Villejuif, France.
- ⁸Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
- ⁹MRC Toxicology Unit, University of Cambridge, Leicester, UK
- ¹⁰Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
- ¹¹Department of Surgical Pathology, Zealand University Hospital, Denmark
- ¹²Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
- ¹³Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
- ¹⁴Department of Pathology, Gustave Roussy, Grand Paris, France.
- ¹⁵Ontario Institute for Cancer Research, Toronto, Canada
- ¹⁶ Institute of Genetics and Molecular Medicine, Edinburgh, UK
- ¹⁷Department of Pathology, St Vincent's University Hospital and University College Dublin, Dublin, Ireland.
- ¹⁸HistoGeneX NV, Antwerp, Belgium
- ¹⁹AZ Sint-Maarten Hospital, Mechelen, Belgium.
- ²⁰Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- ²¹Medical Oncology 2, Istituto Oncologico Veneto - IRCCS, Padova, Italy.
- ²²Department of Pathology, Institut Curie, Paris, France.
- ²³International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.

- ²⁴Department of Pathology, Matsuyama Shimin Hospital, Matsuyama, Japan.
- ²⁵Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.
- ²⁶Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.
- ²⁷Department of Cellular Pathology, North Bristol NHS Trust, Bristol UK
- ²⁸Translational Health Sciences, University of Bristol, UK.
- ²⁹Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina.
- ³⁰Department of Pathology, Hospital de Oncología Maria Curie, Buenos Aires, Argentina
- ³¹Department of Pathology, University of São Paulo, São Paulo, Brazil.
- ³²Department of Pathology, Universidad de La Frontera, Temuco, Chile.
- ³³Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China.
- ³⁴Department of Histopathology, Manipal Hospitals Dwarka, New Delhi.
- ³⁵Breast Surgery, Kansai Medical University Hospital, Hirakata, Japan.
- ³⁶Department of Clinical Genetics and Pathology, Skane University Hospital, Lund University, Lund, Sweden.
- ³⁷Department of Research, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.
- ³⁸Divisions of Medical Oncology, Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- ³⁹Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.
- ⁴⁰Department of Pathology, Breast Pathology Section, Northwestern University, Chicago, USA.
- ⁴¹Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA.
- ⁴²Department of Pathology, Montefiore Medical Center, Bronx, USA.
- ⁴³PhenoPath Laboratories, Seattle, USA.

- ⁴⁴Department of Pathology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.
- ⁴⁵University of Milan, Milan, Italy.
- ⁴⁶Department of Pathology, Dana-Farber Cancer Institute, Boston, USA.
- ⁴⁷Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.
- ⁴⁸Department of Pathology, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy.
- ⁴⁹Department of Biology and Pathology, Centre Jean Perrin, Clermont Ferrand, France.
- ⁵⁰UMR INSERM 1240, Université Clermont Auvergne, Clermont Ferrand, France.
- ⁵¹Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
- ⁵²Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA.
- ⁵³Department of Pathology, Stanford University, Stanford, USA.
- ⁵⁴Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, United States.
- ⁵⁵Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA.
- ⁵⁶Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
- ⁵⁷Department of Pathology, University College London Cancer Institute, University College London, London, UK.
- ⁵⁸Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
- ⁵⁹Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan.
- ⁶⁰Department of Oncology, Mayo Clinic, Rochester, USA.

- ⁶¹Department of Pathology, University Hospital Antwerp, Belgium.
- ⁶²Cancer Biomarkers Working Group, Faculty of Medicine and Pharmacy, Mohamed 1st University, Oujda, Morocco.
- ⁶³Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany.
- ⁶⁴Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA.
- ⁶⁵Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
- ⁶⁶Perlmutter Cancer Center, New York University Medical School, New York, USA.
- ⁶⁷Sichuan Cancer Hospital, Chengdu, China.
- ⁶⁸German Breast Group, Neu-Isenburg, Germany.
- ⁶⁹Department of Oncology, National Taiwan University, Taipei, Taiwan.
- ⁷⁰Faculty of Medicine, The University of Queensland, Centre for Clinical Research, Royal Brisbane and Women's Hospital, Herston, Australia.
- ⁷¹Translational Medicine, Merck & Co, Inc, Kenilworth, USA.
- ⁷²Institute of Pathology, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg and Philipps-Universität Marburg, Marburg, Germany.
- ⁷³Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
- ⁷⁴Department of Radiation Oncology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA.
- ⁷⁵Johanniter GmbH - Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany.
- ⁷⁶Oncology Clinical Development, Bristol-Myers Squibb, Princeton, USA.
- ⁷⁷Translational Medicine, Bristol-Myers Squibb, Princeton, USA.
- ⁷⁸Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia.

⁷⁹Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.

***Correspondence to:** Paula Gonzalez Ericsson, Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA. E-mail: paula.i.gonzalez.ericsson@vumc.org
Melinda Sanders, Department of Pathology, Microbiology and Immunology, and Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA. E-mail: Sanders, Melinda E-mail: melinda.sanders@vumc.org

Short running title: Implementation of PD-L1 and TILs as immuno-oncology biomarkers for breast cancer.

Conflicts of interest: ACM is a consultant and reports research grant support from Bristol-Meyers Squibb. AE is on the Roche advisory board and is a lecturer paid by Roche, Amgen and Novartis. AIH reports honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical and Novartis Pharma. CQ has received speaker fees from Roche and Genomic Health. DLR is on the advisory board for Amgen, Astra Zeneca, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Konica Minolta, Merk, Nanostrings, Perkin Elmer, Roche, Ventana and Ultivue; is a consultant for Biocept, NextCure, Odonate and Sanofi; is a founder and equity hilder of PixelGear; reports research support from Astra Zeneca, Cepheid, Navigigate BioPharma, NextCure, Lilly and Ultivue; instrument support from Ventana, Akoya perkin Elmer and Nanonstrings; travel honorarium from Bristol-Myers Squibb; and royalties from Rarecyte. DZ is an employee of Bristol-Myers Squibb with stock ownership. FPL reports honoraria and funding form Astra Zeneca, BMS, MERCK,

Nanostring, Pfizer and Roche. HM is a consultant for Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi-Sankyo and TapImmune; and has research supported by Bristol-Myers Squibb, MedImmune, LLC AstraZeneca, BTG and Merck. JA is an advisor for AstraZeneca, Bayer, Bristol Myers Squibb, MSD, Roche and Diaceutics, and reports research funding from MSD, Bayer, and Pierre Fabre. JB is a consultant for Insight Genetics Inc, BioNTech AG, Biotheranostics Inc, Pfizer, Rna Diagnostics Inc and oncoXchange; reports honoraria from NanoString Technologies, Oncology Education and Biotheranostics Inc; research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies Inc, Stratifyer GmbH and Biotheranostics Inc; travel expenses from Biotheranostics Inc and NanoString Technologies Inc; and patents regarding biomarker evaluation and gene signatures to predict response to treatment. JMB reports research support from Genentech/Roche, Bristol Myers Squibb and Incyte Corporation, has received consulting expert witness fees from Novartis and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer. JJ is a full-time employee of Merck & Co., Inc. and owns stock in Merck & Co., Inc., Regeneron and Illumina. KE is a full-time employee in Merck & Co., Inc. and owns stock in that company as well as Bayer AG and Johnson & Johnson; his wife is a full-time employee of Bristol Myers Squibb and owns stock in that company. KS reports one-time honorarium from Roche Ventana. MK is on the Advisory board for BMS and Daiichi. OG reports travel support from Roche, Celgene, Daiichi and honoraria advisory boards from Roche, Celgene, Novartis, Pfizer, Lilly, GHI, Nanostring, Amgen and MSD. RLF reports travel Support from Immunomedics. RS reports research funding from Roche Genentech, Puma Biotechnology and Merck, honoraria for consulting for BMS and travel funding from Roche Genentech, Merck and

Astra Zeneca. SE is an employee of Bristol-Myers Squibb with stock ownership. TON has a proprietary interest in the PAM50 subtype classifier from Bioclassifer LLC, Nanostring Technologies.

Acknowledgements: The authors recognize the members of the International Immuno-Oncology Biomarker Working Group for reviewing and providing critical feedback on the manuscript. RS is supported by the Breast Cancer Research Foundation, New York, US. SL is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.

Author contribution statement: RS conceived the presented idea, PGE did the literature search and took the lead in writing the manuscript, with the guidance of RS and MS. All authors provided critical feedback and helped shape the manuscript.

Disclaimer: This work includes contributions from, and was reviewed by, individuals who are personnel of Bristol-Myers Squibb, Merck & Co, Inc and the International Agency for Research on Cancer / World Health Organization. The content is solely the responsibility of the authors and does not necessarily represent the official views or policy of Bristol-Myers Squibb, Merck & Co, Inc or International Agency for Research on Cancer / World Health Organization.

Commented [GEPI1]: I have added the IARC disclaimer